Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04963283	TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Phase Phase 2	Date Added 2021-07-15	Location Colorado, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Cabozantinib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT04948034	TitleThe Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)	Phase Phase 2	Date Added 2021-07-01	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04940546	TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients	Phase Phase 1, Phase 2	Date Added 2021-06-25	Location China	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, capecitabine, oxaliplatin, Sintilimab	Tags MSS/ MMRp
NCT ID NCT04895709	TitleA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors	Phase Phase 1, Phase 2	Date Added 2021-05-20	Location California, United States Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs BMS-936558-01, BMS-986340	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04895722	TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)	Phase Phase 2	Date Added 2021-05-20	Location Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Belgium Canada Colombia Costa Rica Denmark Estonia France Germany Greece Guatemala Hungary Italy Korea, Republic of Lithuania Netherlands Poland Romania Russian Federation Spain Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda	Tags MSI-H/ MMRd
NCT ID NCT04874259	TitleLT for Unresectable Colorectal Liver Metastasis	Phase Not Applicable	Date Added 2021-05-05	Location Korea, Republic of	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04866862	TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer	Phase Phase 2	Date Added 2021-04-30	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Combination of Fruquintinib and Camrelizumab	Tags MSS/ MMRp
NCT ID NCT04853017	TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)	Phase Phase 1	Date Added 2021-04-21	Location California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04793958	TitlePhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)	Phase Phase 3	Date Added 2021-03-11	Location Alabama, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Brazil Canada China Colombia Czechia Denmark Finland France Germany Greece Hong Kong Ireland Italy Korea, Republic of Malaysia Mexico Netherlands Poland Portugal Puerto Rico Romania Singapore Spain Taiwan Thailand Ukraine United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04776148	TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)	Phase Phase 3	Date Added 2021-03-01	Location California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Korea, Republic of Russian Federation Spain Taiwan Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)	Tags MSS/ MMRp

Showing 131 to 140 of 299 entries